Literature DB >> 30016793

Development of a Genetic and Clinical Data-Based (GC) Risk Score for Predicting Survival of Hepatocellular Carcinoma Patients After Tumor Resection.

Shengsen Chen, Chao Wang, An Cui, Kangkang Yu, Chong Huang, Mengqi Zhu, Mingquan Chen.   

Abstract

BACKGROUND/AIMS: Carnitine palmitoyltransferase 1A (CPT1A) is a rate-limiting enzyme in the transport of long-chain fatty acids for β-oxidation. Increasing evidence has indicated that CPT1A plays an important role in carcinogenesis. However, the expression and prognostic value of CPT1A in hepatocellular carcinoma (HCC) have not been extensively studied.
METHODS: Here, we collected 66 post-operative liver cancer tissue samples. Gene profile expression was tested by RT-PCR. Receiver operating characteristic (ROC) analysis was performed and multivariate analysis with Cox's Proportional Hazard Model was used for confirming the selected markers' predictive efficiency for HCC patients' survival. A simple risk scoring system was created based on Cox's regression modeling and bootstrap internal validation.
RESULTS: Cox multivariate regression analysis demonstrated that CPT1A, tumor size, intrahepatic metastasis, TNM stage and histological grade were independent risk factors for the prognosis of HCC patients after surgery. Our genetic and clinical data-based (GC) risk scoring system revealed that HCC patients whose total score≥3 are more likely to relapse and die than patients whose total score < 3. Finally, the good discriminatory power of our risk scoring model was validated by bootstrap internal validation.
CONCLUSIONS: The genetic and clinical data-based risk scoring model can be a promising predictive tool for liver cancer patients' prognosis after operation.
© 2018 The Author(s). Published by S. Karger AG, Basel.

Entities:  

Keywords:  Cpt1a; Hepatocellular carcinoma; PPARΑ; Prognosis; Risk scoring system

Mesh:

Substances:

Year:  2018        PMID: 30016793     DOI: 10.1159/000491779

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  6 in total

1.  Characterization of the Tumor Immune Microenvironment Identifies M0 Macrophage-Enriched Cluster as a Poor Prognostic Factor in Hepatocellular Carcinoma.

Authors:  Mark Farha; Neil K Jairath; Theodore S Lawrence; Issam El Naqa
Journal:  JCO Clin Cancer Inform       Date:  2020-10

2.  NONO promotes hepatocellular carcinoma progression by enhancing fatty acids biosynthesis through interacting with ACLY mRNA.

Authors:  Hongda Ding; Junpeng Liu; Caibin Wang; Yang Su
Journal:  Cancer Cell Int       Date:  2020-08-31       Impact factor: 5.722

3.  Super-enhancer-associated INSM2 regulates lipid metabolism by modulating mTOR signaling pathway in neuroblastoma.

Authors:  Haibo Cao; Ran Zhuo; Zimu Zhang; Jianwei Wang; Yanfang Tao; Randong Yang; Xinyi Guo; Yanling Chen; Siqi Jia; Ye Yao; Pengcheng Yang; Juanjuan Yu; Wanyan Jiao; Xiaolu Li; Fang Fang; Yi Xie; Gen Li; Di Wu; Hairong Wang; Chenxi Feng; Yunyun Xu; Zhiheng Li; Jian Pan; Jian Wang
Journal:  Cell Biosci       Date:  2022-09-16       Impact factor: 9.584

4.  Mechanistic Investigation on the Regulation of FABP1 by the IL-6/miR-603 Signaling in the Pathogenesis of Hepatocellular Carcinoma.

Authors:  Ye-Xin Lin; Xiong-Bo Wu; Chu-Wei Zheng; Qing-Lin Zhang; Guo-Qiang Zhang; Ke Chen; Qiang Zhan; Fang-Mei An
Journal:  Biomed Res Int       Date:  2021-05-15       Impact factor: 3.411

5.  Acylcarnitine: Useful biomarker for early diagnosis of hepatocellular carcinoma in non-steatohepatitis patients.

Authors:  Hiroaki Takaya; Tadashi Namisaki; Mitsuteru Kitade; Naotaka Shimozato; Kosuke Kaji; Yuki Tsuji; Keisuke Nakanishi; Ryuichi Noguchi; Yukihisa Fujinaga; Yasuhiko Sawada; Soichiro Saikawa; Shinya Sato; Hideto Kawaratani; Kei Moriya; Takemi Akahane; Hitoshi Yoshiji
Journal:  World J Gastrointest Oncol       Date:  2019-10-15

6.  Identifying the Prognostic Risk Factors of Synaptojanin 2 and Its Underlying Perturbations Pathways in Hepatocellular Carcinoma.

Authors:  Rui Zhang; Wei-Jia Mo; Lan-Shan Huang; Ji-Tian Chen; Wei-Zi Wu; Wei-Ying He; Zhen-Bo Feng
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.